Inventor
GILLBERG PER-GÖRAN
SE53 patents
Patents
50 patentsUS10487111B2Nov 26, 2019
IBAT inhibitors for the treatment of liver diseases
ALBIREO AB23 citations98
US10093697B2Oct 9, 2018
IBAT inhibitors for the treatment of liver diseases
ALBIREO AB25 citations98
US10011633B2Jul 3, 2018
IBAT inhibitors for the treatment of liver diseases
ALBIREO AB20 citations98
US9694018B1Jul 4, 2017
IBAT inhibitors for the treatment of liver disease
ALBIREO AB47 citations98
US9688720B2Jun 27, 2017
IBAT inhibitors for the treatment of liver diseases
ALBIREO AB27 citations98
US11572350B1Feb 7, 2023
Benzothia(di)azepine compounds and their use as bile acid modulators
ALBIREO AB17 citations95
US11225466B2Jan 18, 2022
Benzothiadiazepine compounds and their use as bile acid modulators
ALBIREO AB23 citations95
US11732006B2Aug 22, 2023
IBAT inhibitors for the treatment of liver diseases
ALBIREO AB11 citations94
US11267794B2Mar 8, 2022
Benzothia(di)azepine compounds and their use as bile acid modulators
ALBIREO AB21 citations94
US11261212B2Mar 1, 2022
IBAT inhibitors for the treatment of liver diseases
ALBIREO AB17 citations94
US11180465B2Nov 23, 2021
Benzothia(di)azepine compounds and their use as bile acid modulators
ALBIREO AB25 citations94
US11111224B2Sep 7, 2021
Benzothia(di)azepine compounds and their use as bile acid modulators
ALBIREO AB30 citations94
US11014898B1May 25, 2021
Benzothiazepine compounds and their use as bile acid modulators
ALBIREO AB30 citations94
US10981952B2Apr 20, 2021
IBAT inhibitors for the treatment of liver diseases
ALBIREO AB20 citations94
US10975045B2Apr 13, 2021
Benzothiazepine compounds and their use as bile acid modulators
ALBIREO AB23 citations94
US10941127B2Mar 9, 2021
Benzothiadiazepine compounds and their use as bile acid modulators
ALBIREO AB28 citations94
US10793534B2Oct 6, 2020
Benzothia(di)azepine compounds and their use as bile acid modulators
ALBIREO AB21 citations94
US10000528B2Jun 19, 2018
IBAT inhibitors for the treatment of liver diseases
ALBIREO AB18 citations94
US10975046B2Apr 13, 2021
Crystal modifications of odevixibat
ALBIREO AB22 citations93
US10221212B2Mar 5, 2019
IBAT inhibitors for the treatment of liver diseases
ALBIREO AB11 citations92
US12187812B2Jan 7, 2025
IBAT inhibitors for the treatment of liver diseases
ALBIREO AB3 citations86
US11891368B2Feb 6, 2024
Benzothia(di)azepine compounds and their use as bile acid modulators
ALBIREO AB10 citations86
US11708340B2Jul 25, 2023
Benzothia(di)azepine compounds and their use as bile acid modulators
ALBIREO AB12 citations86
US11377429B2Jul 5, 2022
Benzothia(di)azepine compounds and their use as bile acid modulators
ALBIREO AB13 citations86
US11773071B2Oct 3, 2023
Benzothiazepine compounds and their use as bile acid modulators
ALBIREO AB14 citations85
US11603359B2Mar 14, 2023
Benzothiadiazepine compounds and their use as bile acid modulators
ALBIREO AB11 citations85
US11306064B2Apr 19, 2022
Benzothia(di)azepine compounds and their use as bile acid modulators
ALBIREO AB17 citations85
US10786529B2Sep 29, 2020
Oral cholestyramine formulation and use thereof
ALBIREO AB12 citations85
US12091394B2Sep 17, 2024
Crystal modifications of odevixibat
ALBIREO AB4 citations84
US11802115B2Oct 31, 2023
Pharmaceutical formulation of odevixibat
ALBIREO AB11 citations84
US11801226B2Oct 31, 2023
Pharmaceutical formulation of odevixibat
ALBIREO AB11 citations84
US11365182B2Jun 21, 2022
Crystal modifications of odevixibat
ALBIREO AB10 citations84
US11583539B2Feb 21, 2023
Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors
ALBIREO AB13 citations83
US10441605B2Oct 15, 2019
Oral cholestyramine formulation and use thereof
ALBIREO AB6 citations83
US10441604B2Oct 15, 2019
Cholestyramine pellets and methods for preparation thereof
ALBIREO AB6 citations83
US12365658B2Jul 22, 2025
Benzothia(di)azepine compounds and their use as bile acid modulators
ALBIREO AB2 citations75
US12202809B2Jan 21, 2025
Benzothia(di)azepine compounds and their use as bile acid modulators
ALBIREO AB4 citations75
US12134606B2Nov 5, 2024
Benzothia(di)azepine compounds and their use as bile acid modulators
ALBIREO AB5 citations75
US12060338B2Aug 13, 2024
Benzothia(di)azepine compounds and their use as bile acid modulators
ALBIREO AB5 citations75
US12024495B2Jul 2, 2024
Benzothiazepine compounds and their use as bile acid modulators
ALBIREO AB5 citations75
US12187690B2Jan 7, 2025
Benzothiadiazepine compounds and their use as bile acid modulators
ALBIREO AB4 citations74
US11007142B2May 18, 2021
Oral cholestyramine formulation and use thereof
ALBIREO AB5 citations72
US10864228B2Dec 15, 2020
Oral cholestyramine formulation and use thereof
ALBIREO AB2 citations72
US10799527B2Oct 13, 2020
Oral cholestyramine formulation and use thereof
ALBIREO AB2 citations72
US10610543B2Apr 7, 2020
Cholestyramine pellets and methods for preparation thereof
ALBIREO AB4 citations72
US10881685B2Jan 5, 2021
Cholestyramine granules, oral cholestyramine formulations and use thereof
ALBIREO AB2 citations67
US12545705B2Feb 10, 2026
IBAT inhibitors for the treatment of liver diseases
ALBIREO AB0 citations62
US10722457B2Jul 28, 2020
Oral cholestyramine formulation and use thereof
ALBIREO AB1 citations62
US12508234B2Dec 30, 2025
Pharmaceutical formulation of odevixibat
ALBIREO AB0 citations61
US12447156B2Oct 21, 2025
Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors
ALBIREO AB0 citations60
Showing the top 50 of 53 patents by PatentIndex Score.